ICU Medical, Inc.
ICUI
Kedudukan dalam Saham
#4007
ICU Medical, Inc., operating globally through its subsidiaries, is a medical... ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
Harga Saham
$162.74
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$4.07B
Perubahan (1 hari)
-2.68%
Perubahan (1 tahun)
37.38%
Negara
US
Perdagangan ICU Medical, Inc. (ICUI)
Kategori
Healthcare
Margin Operasi untuk ICU Medical, Inc. (ICUI)
Margin Operasi pada October 2026 TTM: 5.04%
Menurut laporan kewangan dan harga saham terkini ICU Medical, Inc., margin operasi semasa (TTM) ialah 5.04%. Pada akhir 2023, margin operasi syarikat ialah 1.01%.
Sejarah Margin Operasi untuk ICU Medical, Inc. dari 2000 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | 5.04% | 180.00% |
| 2024 | 1.80% | 78.22% |
| 2023 | 1.01% | -153.72% |
| 2022 | -1.88% | -120.09% |
| 2021 | 9.36% | 21.24% |
| 2020 | 7.72% | 54.71% |
| 2019 | 4.99% | 224.03% |
| 2018 | 1.54% | -231.62% |
| 2017 | -1.17% | -105.35% |
| 2016 | 21.86% | 8.92% |
| 2015 | 20.07% | 59.03% |
| 2014 | 12.62% | -23.79% |
| 2013 | 16.56% | -14.37% |
| 2012 | 19.34% | -10.38% |
| 2011 | 21.58% | 24.60% |
| 2010 | 17.32% | 5.61% |
| 2009 | 16.40% | 6.98% |
| 2008 | 15.33% | 17.02% |
| 2007 | 13.10% | -14.44% |
| 2006 | 15.31% | -12.61% |
| 2005 | 17.52% | 123.75% |
| 2004 | 7.83% | -75.37% |
| 2003 | 31.79% | -6.97% |
| 2002 | 34.17% | 6.68% |
| 2001 | 32.03% | 8.28% |
| 2000 | 29.58% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 31.28% | -93.79% |
US
|
|
| 12.36% | -97.55% |
FR
|
|
| 0.00% | - |
JP
|
|
| 9.83% | -98.05% |
US
|
|
| 0.00% | - |
CH
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.